<DOC>
	<DOCNO>NCT00584402</DOCNO>
	<brief_summary>The purpose study determine efficacy Definity ( perflutren lipid microsphere Injectable Suspension ) ultrasound contrast agent identify small tumor ( hepatoma &amp; metastasis ) within liver . Primary objective : To estimate increase conspicuity small intrahepatic tumor contrast-enhanced sonography Secondary Objectives : To estimate effect tumor type , size , location depth conspicuity small tumor contrast-enhanced sonography</brief_summary>
	<brief_title>Contrast Sonography Evaluation Liver Tumors Prior Radiofrequency Ablation</brief_title>
	<detailed_description>An estimated 75 patient ( age 18 year age old ) enrol population patient present ultrasound-guided radiofrequency ablation ( RFA ) CT MRI-confirmed multiple primary hepatocellular carcinoma ( HCC ) metastatic carcinoma , least one tumor ≤ 1.5 cm diameter .</detailed_description>
	<mesh_term>Liver Neoplasms</mesh_term>
	<criteria>Patients primary hepatocellular carcinoma ( HCC ) secondary ( metastatic ) carcinoma liver refer ultrasoundguided radiofrequency ablation ( RFA ) treatment Recent ( within 90 day ) CT MRI scan report one tumor ≤ 1.5 cm diameter Patient stable manage conservatively ( i.e . nonsurgically ) 18 year age old Ability willingness provide write informed consent Known suspect cardiac shunt ( ) Known sensitivity octafluoropropane Pregnant breastfeeding</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2012</verification_date>
	<keyword>liver cancer</keyword>
</DOC>